Immunotherapy of hepatocellular carcinoma

Published on July 31, 2017   43 min

Other Talks in the Series: Immunotherapy of Cancer

My name is Tim Greten, I'm a senior investigator at the National Cancer Institute in Bethesda, Maryland, and I'm going to give you a presentation entitled Immunotherapy of Hepatocellular Carcinoma.
Hepatocellular carcinoma is a very difficult disease as you can see from the annual death rates in the United States; It's actually one of the top 10 diseases both in male as in female. What is even worse, is if we look at the 10 year mortality trend, you can see here that while the mortality trend is going downwards for a number of diseases, a number of different types of cancers, this is not the case for HCC. You can see both for men and for women, the mortality trend is actually going upwards in the past 10 years. Obviously, this tells us that there is a great need to come up with new treatment options for these type of patients; And what I'm trying to do now is, I'm trying to introduce you to the concept of immunotherapy, but before we go there and talk about immunotherapy for HCC, there is a few comments that I would like to make which explain to you the specifics that we have to consider when we talk about immunotherapy in the context of HCC.